menu
    • menu
    [{"orgOrder":0,"company":"PolTREG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"POLAND","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"PTG-007","moa":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"PolTREG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"PolTREG \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PolTREG \/ Not Applicable"},{"orgOrder":0,"company":"PolTREG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"POLAND","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"PTG-007","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"PolTREG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"PolTREG \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PolTREG \/ Not Applicable"},{"orgOrder":0,"company":"PolTREG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"POLAND","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"PTG-007","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"PolTREG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"PolTREG \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PolTREG \/ Not Applicable"},{"orgOrder":0,"company":"PolTREG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"POLAND","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"PTG-007","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"PolTREG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"PolTREG \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PolTREG \/ Not Applicable"},{"orgOrder":0,"company":"PolTREG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"CAR-Treg Cell Therapy","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"PolTREG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"PolTREG \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PolTREG \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by PolTREG

    Menu

    PolTREG

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PolTREG

                            Poland arrow
                            Biotech Digital Meet
                            Not Confirmed

                            PolTREG

                            Poland arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PTG-007,Rituximab

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PolTREG Launches Phase 2 Cell Therapy Trial in Children with Presymptomatic Diabetes

                            Details : PTG-007 is an Advanced Therapy Medicinal Product (ATMP), which serves as a platform to develop therapies for a wide range of autoimmune diseases, including presymptomatic type-1 diabetes (T1D).

                            Product Name : PTG-007

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 24, 2024

                            Lead Product(s) : PTG-007,Rituximab

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PolTREG

                            Poland arrow
                            Biotech Digital Meet
                            Not Confirmed

                            PolTREG

                            Poland arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR-Treg Cell Therapy

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PolTREG Starts Preclinical CAR-Treg Development for Neuroinflammatory Autoimmune Diseases

                            Details : PolTREG’s CAR-Treg cells will be developed using the same technology platform as its lead product PTG-007, a polyclonal Treg cell therapy for treating neuroinflammatory autoimmune diseases.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 26, 2024

                            Lead Product(s) : CAR-Treg Cell Therapy

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PolTREG

                            Poland arrow
                            Biotech Digital Meet
                            Not Confirmed

                            PolTREG

                            Poland arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PTG-007,Rituximab

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PolTREG Cell Therapy Shows Long-Term Remission in Type 1 Diabetes Patients

                            Details : PTG-007, an autologous Treg treatment, resulted in clinical remission for up to 12 years in patients with type-1 diabetes (T1D) in combination with a standard anti-CD20 treatment (rituximab).

                            Product Name : PTG-007

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 09, 2024

                            Lead Product(s) : PTG-007,Rituximab

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            PolTREG

                            Poland arrow
                            Biotech Digital Meet
                            Not Confirmed

                            PolTREG

                            Poland arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PTG-007,Rituximab

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PolTREG’s PTG-007 Shows Long-Term Safety in Type-1 Diabetes Treatment

                            Details : PTG-007, a treg cell therapy, in combination with rituximab, a CD20 inhibitor, is being investigated in a phase 1/2 trial for the treatment of type-1 diabetes.

                            Product Name : PTG-007

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 24, 2024

                            Lead Product(s) : PTG-007,Rituximab

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            PolTREG

                            Poland arrow
                            Biotech Digital Meet
                            Not Confirmed

                            PolTREG

                            Poland arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PTG-007,Rituximab

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PolTREG Identifies Efficacy Biomarker for Type-1 Diabetes Treated with Treg Therapy

                            Details : PTG-007, a treg cell therapy, in combination with rituximab, a CD20 inhibitor, is being investigated in a phase 1/2 trial for the treatment of type-1 diabetes.

                            Product Name : PTG-007

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            April 04, 2024

                            Lead Product(s) : PTG-007,Rituximab

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth